Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

Ho, J., D. Schmidt, T. Lowinus, J. Ryoo, E. P. Dopfer, N. Gonzalo Nunez, S. Costa-Pereira, C. Toffalori, M. Punta, V. Fetsch, T. Wertheimer, M. C. Rittmann, L. M. Braun, M. Follo, C. Briere, J. M. Vinnakota, M. Langenbach, F. Koppers, K. Shoumariyeh, H. Engel, T. Ruckert, M. Marklin, S. Holzmayer, A. L. Illert, F. Magon, G. Andrieux, S. Duquesne, D. Pfeifer, J. Staniek, M. Rizzi, C. Miething, N. Kohler, J. Duyster, H. D. Menssen, M. Boerries, J. M. Buescher, N. Cabezas-Wallscheid, B. R. Blazar, P. Apostolova, L. Vago, E. L. Pearce, B. Becher, and R. Zeiser. 2022. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood 140: 1167-1181. doi: 10.1182/blood.2022016082.

Categorised in:

This post was written by Heike Ufheil